Drug intelligence / Profile preview

SPSO-1004

Development stage: Preclinical
Lead developer: Spriaso

Overview

SPSO-1004 is an investigational drug candidate being developed by **Spriaso LLC** for the treatment of gastrointestinal (GI) disorders. Spriaso is a biopharmaceutical company specializing in therapeutics for central nervous system (CNS) and digestive system conditions, often focusing on unique delivery platforms to enhance patient compliance. As of early 2024, SPSO-1004 is in the preclinical or early clinical development stage. Specific details regarding its molecular target, biological modality, and precise mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on SPSO-1004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPSO-1004.

Explore the full profile